Veritas In Silico Inc.(130A) News

Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction

Organizational Reforms and Personnel Changes

[Summary] Financial Results for the Nine Months

Financial Results - Fiscal Year Ending December 2025, 3rd Quarter　

Veritas In Silico, Jan-Sep (Cumulative 3Q) Ordinary Profit Loss Widens, Jul-Sep Ordinary Profit Loss Widens

Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP]

Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic

Revised Financial Forecast for FY2025

Veritas In Silico, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss

Relocation of the Shin-Kawasaki Research Institute

The Jikei University School of Medicine and VIS announce Start of Joint Research for Fundamentally Enhancing Therapeutic Effects of Pharmaceuticals

Nomination of a Candidate for Independent Outside Director

Financial Results - Fiscal Year Ended December 31, 2025, 2nd Quarter

Veritas In Silico, First Half Ordinary Profit Loss Widens, Apr-Jun Ordinary Profit Loss Widens

Non-consolidated Financial Results for the Six Months Ended June 30, 2025 [Under Japanese GAAP]

Patent owned by Veritas In Silico receives Notice of Allowance in the U.S.

Mitsubishi Gas Chemical and VIS Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs

Determination of Target Disease for mRNA-Targeted Nucleic Acid Drug for In-house Pipeline

Shionogi and Veritas In Silico Announce Milestone Achievement in Joint Drug Discovery Research of mRNA-targeted Small Molecules

Financial Results - Fiscal Year Ended December 31,2025, 1st Quarter